Sandra Burchett

Sandra Burchett, MD, MSc

Senior Associate Physician in Medicine; Clinical Director, Division of Infectious Diseases; Director, Children's Hospital AIDS Program (CHAPS); Director, Immunocompromised Host Service

Associate Professor of Pediatrics, Harvard Medical School

  • Contact: 617-355-6832

  • Fax: 617-730-0911

Medical Services

Specialties

  • Congenital Infections
  • Infections in Immunocompromised Children
  • Neonatal Infections
  • HIV
  • Infectious Disease

Departments

  • Infectious Diseases
  • Medicine

Programs

  • Children's Hospital AIDS Program (CHAP)
  • Division of Infectious Diseases
  • Immunocompromised Host Service
  • Perinatal Diagnostic Program
To schedule an appointment: Call 617-355-6832

Experience and Education

Education

Graduate School

University of Arkansas,

Little Rock, AR

Medical School

University of Arkansas College of Medicine,

Little Rock, AR

Internship

Arkansas Children's Hospital,

Little Rock, AR

Residency, Pediatrics

Arkansas Children's Hospital,

Little Rock, AR

Fellowship, Pediatric Infectious Diseases

University of Washington Medical Center,

Seattle, WA

Certifications

  • Pediatric Infectious Diseases

Publications

Publications powered by Harvard Catalyst Profiles
  1. Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2016 Jul 1; 72(3):289-96.
  2. Agwu AL, Yao TJ, Eshleman SH, Patel K, Huang W, Burchett SK, Siberry GK, Van Dyke RB. Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy. Pediatr Infect Dis J. 2016 Jul; 35(7):777-81.
  3. Van Dyke RB, Patel K, Kagan RM, Karalius B, Traite S, Meyer WA, Tassiopoulos KK, Seage GR, Seybolt LM, Burchett S, Hazra R. Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. Clin Infect Dis. 2016 Jul 1; 63(1):133-7.
  4. Gantt S, Leister E, Jacobsen DL, Boucoiran I, Huang ML, Jerome KR, Jourdain G, Ngo-Giang-Huong N, Burchett S, Frenkel L. Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy. J Med Virol. 2016 Jun; 88(6):1051-8.
  5. Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R. Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. Clin Infect Dis. 2016 Jan 1; 62(1):106-14.
  6. Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. J Acquir Immune Defic Syndr. 2015 Sep 1; 70(1):33-41.
  7. Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15; 61(10):1582-9.
  8. Siberry GK, Patel K, Bellini WJ, Karalius B, Purswani MU, Burchett SK, Meyer WA, Sowers SB, Ellis A, Van Dyke RB. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. Clin Infect Dis. 2015 Sep 15; 61(6):988-95.
  9. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11.
  10. Kapetanovic S, Aaron L, Montepiedra G, Anthony P, Thuvamontolrat K, Pahwa S, Burchett S, Weinberg A, Kovacs A. Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy. PLoS One. 2015; 10(3):e0120474.
  11. Show all
  12. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 1; 67(4):375-81.
  13. Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman D, Siberry GK, Van Dyke RB, Burchett S, Seage GR, Luzuriaga K. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 2014 Dec; 168(12):1138-46.
  14. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83.
  15. Schwenk H, Ramirez-Avila L, Sheu SH, Wuthrich C, Waugh J, Was A, Degirolami U, Burchett S, Koralnik IJ, Ahmed A. Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review. Pediatr Infect Dis J. 2014 Apr; 33(4):e99-105.
  16. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jun; 19(7):1441-9.
  17. Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr. 2013 May 1; 63(1):59-66.
  18. Lo MS, Lee GM, Gunawardane N, Burchett SK, Lachenauer CS, Lehmann LE. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013 Mar; 17(2):133-43.
  19. Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis. 2012 Aug 1; 206(3):421-30.
  20. Kapetanovic S, Aaron L, Montepiedra G, Burchett SK, Kovacs A. T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children. AIDS. 2012 May 15; 26(8):959-69.
  21. Miller TI, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, Van Dyke RB, Worrell CJ, Jacobson DL, Shearer W, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Patton D, Burchett S, Karthas N, Kammerer B, Yogev R, Malee K, Hunter S, Cagwin E, Wiznia A, Burey M, Nozyce M, Chen J, Gobs E, Grant M, Knapp K, Allison K, Garvie P, Acevedo-Flores M, Rios H, Olivera V, Silio M, Borne C, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Barr E, Chambers C, Watson D, Messenger N, Belanger R, Dieudonne A, Bettica L, Adubato S, Scott G, Himic L, Willen E. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012 May; 13(5):264-75.
  22. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS, Jennings A, Barr E, Smith E, Rossi SS, Mirochnick M. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012 Apr; 13(4):226-35.
  23. Ehlinger EP, Webster EM, Kang HH, Cangialose A, Simmons AC, Barbas KH, Burchett SK, Gregory ML, Puopolo KM, Puopolo KP, Permar SR. Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants. J Infect Dis. 2011 Dec 1; 204(11):1672-82.
  24. Siberry GK, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, Paul ME, Read JS, Wiznia A, Seage GR. CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr. 2011 Jul 1; 57(3):223-9.
  25. Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. 2011 Jun 1; 57(2):165-73.
  26. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011 Apr 15; 56(5):412-9.
  27. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011 Apr 15; 52(8):1003-9.
  28. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010 Aug; 54(4):381-8.
  29. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):285-9.
  30. Brogly SB, Foca M, Deville JG, Mirochnick M, Scott GB, Mofenson LM, Read JS, Viani RM, Burchett SK, Cooper ER, Browning R, Shapiro DE. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):154-7.
  31. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8.
  32. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. . CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1-Infected Children Receiving Highly Active Antiretroviral Therapy. . J Acquir Immune Defic Syndr. . 2009.
  33. Kamin DS, Burchett S, Kim HB. Case 15-2009: a man with coma after cardiac arrest. N Engl J Med. 2009 Aug 13; 361(7):725; author reply 725.
  34. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009 Feb; 104(2):444-53.
  35. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):485-91.
  36. Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008 Nov; 9(10):875-82.
  37. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20.
  38. Brookie Best, A Stek, C Hu, S Burchett, S Rossi, E Smith, B Sheeran, J Read, E Capparelli, and M Mirochnick for the PACTG/IMPAACT P1026s Team. High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy and Postpartum. 15th Conference on Retroviruses and Opportunistic Infections. 2008; 629.
  39. Akihiko Saitoh, E Sarles, E Capparelli, F Aweeka, A Kovacs, S Burchett, A Wiznia, S Nachman, T Fenton, and S Spector. CYP2C19 Genetic Variants Affect Nelfinavir and M8 Pharmacokinetics and Virologic Response in HIV-1 Infected Children Receiving HAART. 15th Conference on Retroviruses and Opportunistic Infections. 2008; 572.
  40. Handelsman E, Cheng I, Thompson B, Hershow R, Mofenson LM, Hollinger FB, Chen KT, Burchett SK, Klinzman D, Stapleton JT. Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. HIV Med. 2007 Nov; 8(8):561-7.
  41. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18; 21(16):2191-9.
  42. Burchett SK and Dalgic N. Viral Infections. Manual of Neonatal Care, Cloherty, Eichenwald, Stark, eds. 2007.
  43. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet. 2007 Jul 7; 370(9581):68-80.
  44. Jennifer Read, B Best, A Stek, C Hu, E Capparelli, D Holland, S Burchett, E Smith, B Sheeran and M Mirochnick. Nelfinavir Pharmacokinetics (625-mg Tablets) during the Third Trimester of Pregnancy and Post-partum. 14th Conference on Retroviruses and Opportunistic Infections. 2007; 740.
  45. Sandra Burchett, B Bestm M Mirochnick, C Hu, E Capparelli, C Fletcher, E Smith, B Sheeran, J Read, A Stek, for the PACTG 1026s Team. Tenofovir Pharmacokinetics during Pregnancy, at Delivery and Postpartum. 14th Conference on Retroviruses and Opportunistic Infections. 2007; 738b.
  46. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 3; 20(15):1931-9.
  47. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006 Feb 28; 20(4):553-60.
  48. M Mirochnick, A Stek, E Capparelli, B Best, D Holland, J Connor, SK Burchett, et al. . Lopinavir exposure with a higher dose during the 3rd trimester of pregnancy. 13th Conference on Retroviruses and Opportunistic Infections. 2006.
  49. Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J of Infec Disease. 2005; 192(2):296-302.
  50. Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, Yu XG, Verrill C, Allen T, Moore C, Mallal S, Burchett S, McIntosh K, Pelton SI, St John MA, Hazra R, Klenerman P, Altfeld M, Walker BD, Goulder PJ. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol. 2005 Jun 15; 174(12):7524-30.
  51. Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005 Jul 15; 192(2):296-302.
  52. Weinberg G and Burchett SK . Pediatric Human Immunodeficiency Virus Infection. Principles and Practice of Infectious Diseases, Mandell G, Bennett J, Dolin R, eds. 2005; 1638-54.
  53. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mahias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK . Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: pediatric AIDS clinical trials group protocol 332. Journal of Infectious Diseases . 2004; 190(12):2167-74.
  54. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004 Dec 15; 190(12):2167-74.
  55. Stek A, Mirochnick M, Capparelli E, Best B, Burchett S, et al. PACTG 1026 team . Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. International AIDS Conference. 2004; Bangkok.
  56. Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK. Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004 Jul 1; 39(1):107-14.
  57. Shapiro D, Tuomala R, Pollack H, Burchett S, Read J, Cababasay M, McNamara J, Ciupak G . Mother-to child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 US women (PACTG 367). 11th Conference on Retroviruses and Opportunistic Infections. 2004; San Francisco:A99.
  58. Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK, Pediatric AIDS Clinical Trials Group 366 Team . Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clinical Infectious Diseases . 2004; 39(1):107-14.
  59. Soh CH, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, Foca MD, Handelsman E, Jiménez E, Dankner WM, Hughes MD. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003 Dec 20; 362(9401):2045-51.
  60. Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol. 2003 Dec 15; 171(12):6968-75.
  61. Burchett SK and Pizzo PA . HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 24:186-93.
  62. Feeney ME, Roosevelt KA, Tang Y, Pfafferott KJ, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ. Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. J Virol. 2003 Jul; 77(13):7492-501.
  63. Burchett SK, Pizzo PA. HIV infection in infants, children, and adolescents. Pediatr Rev. 2003 Jun; 24(6):186-94.
  64. Burchett SK . Congenital Infections. Manual of Pediatric Practice, Finberg L, editor. 2003.
  65. Burchett SK . Viral Infections. Manual of Neonatal Care, Cloherty JP and Stark AR, editors. 2003; 255-86.
  66. Wade N, Unadkat J, Huang S, Shapiro D, Yasin S, Mathias A, Samelson R, Bryson Y, Mofenson L, Watts H, Smith M, Burchett S. Pharmakokinetics and Safety of d4T and 3TC in HIV-infected Pregnant Women and Their Infants (PACTG 332). 10th Conference on Retroviruses and Opportunistic Infections. 2003; Boston:A886.
  67. Feeney ME, Day CL, Roosevelt KA, McIntosh K, Burchett S, et al. . Robust Gag-specific T-helper Response Associated with Viral Control in Pediatric HIV Infection. 10th Conference on Retroviruses and Opportunistic Infections. 2003; Boston:A299.
  68. Burchett SK and Pizzo PA . HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 24:186-194.
  69. Burchett SK . Perinatal Infections. Saunders Manual of Pediatric Practice, Finberg L. and Kleinman RE, editors. 2002; 356-61.
  70. Shapiro D, Tuomala R, Samelson R, Burchett S, Ciupak G, McNamara J, Pollard H, Read J . Mother-to-Child HIV Transmission Rates According to Antiretroviral Therapy, Mode of Delivery and Viral Load (PACTG 367). 9th Conference on Retroviruses and Opportunistic Infections. 2002; Seattle:A114.
  71. Working Group. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Health Services/Technology Assessment Text. 2001.
  72. Goulder PJ, Pasquier C, Holmes EC, Liang B, Tang Y, Izopet J, Saune K, Rosenberg ES, Burchett SK, McIntosh K, Barnardo M, Bunce M, Walker BD, Brander C, Phillips RE. Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. Immunol Lett. 2001 Nov 1; 79(1-2):109-16.
  73. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis. 2001 Nov 15; 184(10):1331-5.
  74. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 2001 Jul 19; 412(6844):334-8.
  75. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001 May; 107(5):E77.
  76. Frenkel LM, Burchett SK, Aldrovandi GM, et al. HIV-1 Reverse Transcriptase M184V/I Improves the Rate of Suppression of Viral Replication by Salvage Therapy. 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A463.
  77. Kovacs A, Burchett S, Khoury M, et al. . Virologic and Immunologic Responses in Children with Advanced HIV Disease on a New HAART Regimen (PACTG 366). 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A684.
  78. Weinberg A, Kovacs A, Pahwa S, Carey V, Oyomopito R, Mofenson L, Khoury M, Zimmer B, Burchett S. HIV-Infected Children on HAART Reconstitute Tetanus-Specific T Cell Responses without Booster Vaccination. 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A688.
  79. Goulder PJ, Jeena P, Tudor-Williams G, Burchett S. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br Med Bull. 2001; 58:89-108.
  80. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA . Human immunodeficiency virus type 1 (HIV-1) gp 120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. Journal Infectious Diseases. 2001; 184:1331-5.
  81. Goulder PJ, Jeena P, Tudor-Williams G, Burchett S . Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. British Medical Bulletin . 2001; 58:89-108.
  82. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL . The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics . 2001; 107:E77.
  83. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL . The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. International Journal of STD and AIDS . 2001; 12:767.
  84. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med. 2000 Dec 18; 192(12):1819-32.
  85. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thompson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis. 2000 Dec; 182(6):1616-24.
  86. Lindsey JC, Hughes MD, McKinney RE, Cowles MK, Englund JA, Baker CJ, Burchett SK, Kline MW, Kovacs A, Moye J. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis. 2000 Nov; 182(5):1385-93.
  87. Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman KE, O'Callaghan CA, Ogg GS, Altfeld MA, Rosenberg ES, Cao H, Kalams SA, Hammond M, Bunce M, Pelton SI, Burchett SA, McIntosh K, Coovadia HM, Walker BD. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol. 2000 Jun; 74(12):5679-90.
  88. Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group. Antimicrob Agents Chemother. 2000 Apr; 44(4):1041-6.
  89. Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, Van Dyke R, Jimenez E. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis. 2000 Mar; 181(3):890-6.
  90. Burchett SK, Khoury M, McIntosh K, Carey SV, Oyomopito R, Mofenson L, Smith E, Kovacs A . Viral load reduction (VLR) in children with advanced HIV disease treated with 4-drug antiretroviral treatment (ART) regimens including NRTIs, Nevirapine (NVP), Nelfinavir (NFV), and/or Ritonavir (RTV):PACTG 366. 7th Conference on Retroviruses and Opportunistic Infections. 2000; San Francisco:A698.
  91. Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, Burchett S. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis. 2000 Feb; 181(2):548-54.
  92. Tuomala R, Shapiro D, Samelson R, Burchett S, Cuipak G, McNamara J, Pollack H, Read J . Antepartum antiretroviral therapy and viral load in 464 HIV-infected women in 1998-1999 (PACTG 367). American Journal of Obstetrics and Gynecology. 2000; 182:S99.
  93. Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SK, McIntosh K, Walker BD, Goulder PJ . Identification of dominant optimal HLA-B6-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. Journal Virology. 2000; 74:8541-9.
  94. Stiehm ER, Fletcher CV, Mofenson L, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, Burchett S . Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type-1 infected children (Pediatric AIDS clinical trials group protocol 273). Journal Infectious Diseases. 2000; 181:548-54.
  95. Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS . Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The pediatrics AIDS clinical trials group. Antimicrobial Agents Chemotherapy. 2000; 44:1041-6.
  96. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thomson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The pediatric AIDS clinical trials group. Journal Infectious Dissease . 2000; 182:1616-24.
  97. The Perinatal Safety Review Working Group . Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. Journal Acquired Immunodeficiency Syndrome . 2000; 25:261-8.
  98. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O’Callaghan CA, Kalams SA, McKinney RE Jr, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. Journal Experimental Medicine . 2000; 192:1819-32.
  99. Samelson R, Shapiro D, Tuomala R, Burchett S, Ciupak G, McNamara J, Pollack H, Read J . HIV vertical transmission rates according to antiretro-viral therapy and viral load during pregnancy among 347 mother-child pairs 1998-99 (PACTG 367). American Journal of Obstetrics and Gynecology. 2000; 182:S97.
  100. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999 Aug 5; 341(6):394-402.
  101. Ngo LY, Yogev R, Dankner WM, Hughes WT, Burchett S, Xu J, Sadler B, Unadkat JD. Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Antimicrob Agents Chemother. 1999 Jun; 43(6):1516-9.
  102. Burchett SK, Kovacs A, Khoury M, Yong F, Carey V, Smith ME, Mofenson L, Zimmer B, Hawkins E . Preliminary toxicity and tolerability of 4-drug antiretroviral (ARV) therapy with NRTIs, Nevirapine (NVP), Nelfinavir (NFV) and Ritonavir (RTN) in ARV-experienced children with advanced HIV disease. 6th Conference on Retroviruses and Opportunistic Infections. 1999; Chicago.
  103. Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, Smith B, Mofenson L, Sullivan JL. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol. 1999 Jan; 73(1):362-7.
  104. Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, Smith B, Mofenson L, Sullivan JL . Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. Journal of Virology . 1999; 73:362-7.
  105. Palumbo P and Burchett SK . Diagnosis of HIV Infection and Markers of Disease Progression in Infants. Pediatric AIDS, Pizzo P and Wilfert C, editors. 1998; 67-87.
  106. Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol. 1998 Nov 2; 91(1-2):19-27.
  107. Burchett SK . Viral Infections. Manual of Neonatal Care, Cloherty JP and Stark AR, editors. 1998; 239-71.
  108. Burchett SK. Congenital Infections. Saunders Manual of Pediatric Practice, Finberg L, editor. 1998; 299-302.
  109. Burchett SK, Sullivan J, Carey V, Yong F, Culnane M, Mofenson L, Robinson P, Luzuriaga K . Combinations of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) can reduce CSF HIV-1 viral load in pediatric patients with advanced HIV disease. 12th World AIDS Conference. 1998; Geneva.
  110. Garcia PM, Kalish L, Pitt J, Quinn T, Burchett S, Hanson C, Minkoff H, Jackson B, Moye J, Lew J . Maternal human immunodeficiency virus (HIV) RNA level correlates with the risk but does not predict the timing of perinatal transmission. American Journal of Obstetrics and Gynecology. 1998; 178:2S.
  111. Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, Brown ZA, Corey L. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol. 1997 Aug; 177(2):450-4.
  112. Zaknun D, Orav J, Kornegay J, al-Attar I, Fuchs D, Zaknun J, Wachter H, Chatis P, Burchett SK, McIntosh K. Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. J Pediatr. 1997 Jun; 130(6):898-905.
  113. Frenkel LM, Cowles MK, Shapiro DE, Melvin AJ, Watts DH, McLellan C, Mohan K, Murante B, Burchett S, Bryson YJ, O'Sullivan MJ, Mitchell C, Landers D. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997 Apr; 175(4):971-4.
  114. Melvin AJ, Tamura GS, House JK, Hobson AC, Cone RW, Frenkel LM, Burchett S. Lack of detection of human immunodeficiency virus type 1 in the saliva of infected children and adolescents. Arch Pediatr Adolesc Med. 1997 Mar; 151(3):228-32.
  115. Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1; 14(3):232-6.
  116. Burchett SK, Carey V, Yong F, Sullivan J, Sulzbacher S, Civitello L, Culnane M, Mofenson L, Siminski S, Robinson P, Luzuriaga K . Virologic activity of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245). 5th Conferemce on Retroviruses and Opportunistic Infections. 1997; Chicago(Abst 271):A998.
  117. Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW . Effect of pregnancy and zidovudine therapy on viral load in HIV-I-infected women. Journal Acquired Immune Deficiency Syndrome Human Retrovirology. 1997; 14:232-6.
  118. Zaknun D, Orav J, Kornegay J, al-Attar I, Fuchs D, Zaknun J, Wachter H, Chatis P, Burchett SK, McIntosh K . Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. Journal Pediatrics. 1997; 130:898-905.
  119. Frenkel LM, Cowles MK, Shapiro DE, Melvin AJ, Watts DH, McLellan C, Mohan K, Murante B, Burchett S, Bryson YJ, O’Sullivan MJ, Mitchell C, Landers D . Analysis of the maternal components of the AIDS clinical trials group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. Journal Infectious Disease. 1997; 175:971-4.
  120. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, Burchett SK. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J. 1996 Dec; 15(12):1087-91.
  121. Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996 Dec; 174(6):1162-7.
  122. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J. 1996 Mar; 15(3):247-54.
  123. Pohl-Koppe A, McIntosh K, Burchett SK . Interferon gamma and IL-6 secretion of peripheral blood mononuclear cells is significantly increased in infants with perinatal HIV infection. 3rd National Human Retroviruses and Related Infections Conf. 1996; Washington DC.
  124. Pohl-Koppe A, Burchett SK, Hafler DA . Functional characterization of autoreactive T-cells in acute disseminated encephalomyelitis. Pediatric Research. 1996; 40:548.
  125. Jones CA, Burchett SK . Lack of correlation between CMV infection and central neurological compromise in HIV-infected children. 3rd National Human Retroviruses and Related Infections Conference. 1996; Washington DC.
  126. DeVincenzo JP, Burchett SK . Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral apthhous ulcers. Pediatric Infectious Disease Journal. 1996; 15:465-7.
  127. Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ . Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National institute of allergy and infectious diseases and infectious diseases collaborative antiviral study group. Journal Infectious Diseases. 1996; 174:1162-7.
  128. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R . Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatric Infectious Disease Journal. 1996; 15:247-54.
  129. Burchett SK, Luzuriaga K, Culnane M, Mofenson L, Carey V, Yong F, Siminski S . Early Toxicity Experience in Combination Therapy of Advanced Pediatric HIV Disease. 35th ICAAC Conference. 1995; San Francisco.
  130. McIntosh K, Burchett SK. Clearance of HIV--lessons from newborns. N Engl J Med. 1995 Mar 30; 332(13):883-4.
  131. McIntosh K, Burchett SK . Clearance of HIV: Lessons from newborns. New England Journal Medicine. 1995; 332:883-4.
  132. Burchett S, Mohan K, Melvin A, Coombs R., Sulzbacher S . Correlates of CNS Disease Progression in Children Vertically-Infected with HIV. 2nd National Human Retroviruses and Related Infections Conference. 1995; Washington DC.
  133. Burchett SK, Mohan K, Melvin A, Coombs R, Corey L . Defining Pediatric "Rapid HIV Progressors" by Plasma Viremia and Sequential Western Blot. 34th ICAAC Conference. 1994; Orlando.
  134. Burchett SK. Protective Immunity. Perinatal and Pediatric Pathophysiology, A Clinical Perspective; Gluckman PB and Heymann MA, editors. 1993; 669-73.
  135. Burchett SK, Gretch D, Fleming J, Dela Rosa C, Watts H, Corey . Maternal hepatitis C (HCV) infection is not a cofactor for enhanced rate of vertical transmission of HIV-I. 9th International Conference AIDS. 1993; Berlin.
  136. Burchett S . The Placental Barrier to HIV-1 Transmission. The AIDS Reader. 1993; Sept/Oct:163-5.
  137. Henrard DR, Phillips J, Burchett S, Jackson JB, Kataaha P, Mmiro F, Ndugwa C. Plasma viral load in symptom-free women and vertical transmission of HIV-1. Lancet. 1992 Dec 12; 340(8833):1470-1.
  138. Watts DH, Burchett SK, Coombs RW, Brown ZA, Corey L . Correlates of vertical transmission of human immunodeficiency virus (HIV). Inf Dis Soc for Obstet-Gynec. 1992.
  139. Burchett SK, Gretch D, Fleming J, Coombs R, Corey L . Maternal hepatitis C (HCV) infection does not enhance the rate of vertical transmission of HIV. 32nd ICAAC Conference. 1992; Anaheim.
  140. Ashley RL, Dalessio J, Burchett S, Brown Z, Berry S, Mohan K, Corey L. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest. 1992 Aug; 90(2):511-4.
  141. Burchett SK, Henrard D, Watts DH, Melvin A, Fleming J, Stamateou J, Coombs RW. Early diagnosis of HIV in infants born to seropositive women. 8th International Conference on AIDS/STD World Congress. 1992; Amsterdam.
  142. Burchett SK, Corey L, Mohan KM, Westall J, Ashley R, Wilson CB. Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. J Infect Dis. 1992 May; 165(5):813-8.
  143. Burchett SK . The role of the placental macrophage in prevention of vertical transmission of HIV. Keystone Conference on Pediatric AIDS. 1992.
  144. Bratton S, Krane E, Park J, Burchett S . Clostridium septicum infections in children. Pediatric Infectious Diseases Journal. 1992; 11:569-75.
  145. Burchett SK, Coombs RC, Mohan K, Watts H, Warren K, Corey L. Culture: An early diagnostic tool in infants born to HIV infected women. 31st ICAAC Conference. 1991; Chicago.
  146. Burchett SK, Coombs RC, Warren K, Watts HD, Wilson C, Corey L . Diminished ability of fetal and neonatal macrophages to support proliferative human immunodeficiency infection. Clin Res. 1991; 39:382A.
  147. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Vontver LA, Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991 May 2; 324(18):1247-52.
  148. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, Starr S, Jacobs R, Powell D, Nahmias A, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):450-4.
  149. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):444-9.
  150. Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, Corey L. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991 Feb; 163(2):226-32.
  151. Burchett SK, Coombs R, Stamateou J, Watts HD, Wilson C, Corey L . Comparative susceptibility of neonatal lymphocytes and monocytes to HIV infection. 30th ICAAC. 1990; Atlanta.
  152. Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK. Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J Clin Invest. 1990 Jun; 85(6):1914-24.
  153. Watts H, Burchett SK . HIV infection in pregnancy and infancy in AIDS. Diagnosis and treatment. Handbook of AIDS Treatment, Holmes KK, Collier A, Corey L, Handsfield H, editors. 1990; 160-63.
  154. Reiner NE, NG W, Wilson CB, McMaster WR, Burchett SK . Modulation of in vitro monocyte cytokine responses during infection with Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. Journal Clinical Investigation. 1990; 85:1914-24.
  155. Burchett S, Coombs R, Chaloupka K, Stamateou J, Wilson C, Mohan K, Corey L , 1989; Montreal. Association between plasma human immunodeficiency virus type-1 (HIV) viremia and clinical class of pediatric HIV infection. 5th International Conference on AIDS. 1989; Montreal.
  156. Corey L, Brown Z, Burchett S, Wolf ME . The use of antiviral drugs in pregnancy for herpes simplex virus infections. Antiviral Chemotherapy, Mills J, Corey L, editors. 1989; 2:23-36.
  157. English BK, Burchett SK, English JD, Ammann AJ, Wara DW, Wilson CB. Production of lymphotoxin and tumor necrosis factor by human neonatal mononuclear cells. Pediatr Res. 1988 Dec; 24(6):717-22.
  158. Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol. 1988 May 15; 140(10):3473-81.
  159. Tabor DR, Burchett SK, Jacobs RF. Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. Proc Soc Exp Biol Med. 1988 Apr; 187(4):408-15.
  160. Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. . Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. Journal of Immunology. 1988; 140:3473-81.
  161. Tabor DR, Burchett SK, Jacobs RF . Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. Proceedings Society Experimental Biology Medicine. 1988; 187:408-15.
  162. Glover DM, Brownstein D, Burchett S, Larsen A, Wilson CB. Expression of HLA class II antigens and secretion of interleukin-1 by monocytes and macrophages from adults and neonates. Immunology. 1987 Jun; 61(2):195-201.
  163. Woody RC, Burchett SK, Steele RW, Sullivan JA, McConnell JR. The role of computerized tomographic scan in the management of Gradenigo's syndrome: a case report. Pediatr Infect Dis. 1984 Nov-Dec; 3(6):595-7.
  164. Burchett SK, Marmer DJ, Steele RW, Jacobs RF, Elders MJ, Kemp SF. Immunologic profile of growth hormone deficient children before and during growth hormone replacement. Clin Res. 1984; 32(5):A895.
To schedule an appointment: Call 617-355-6832

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close